Anticancer Bioscience completed the approval of its IND application in China.

We are Anticancer Bioscience (ACB), Ltd., a growing precision therapeutics company headquartered in Chengdu, China, with global research and development teams in India, the United Kingdom, and the United States. The company is dedicated to the development of synthetic lethal therapies that address unmet medical needs. Our most advanced programs are synthetic lethal therapies for cancer. Genetic perturbations that fuel cancer growth can also introduce an over-dependence for the cancer cell on pathways and proteins that the normal, non-cancerous cell does not have. Anticancer Bioscience was founded by scientists that are experts in identifying and exploiting these cancer vulnerabilities. We have assembled a talented team of medicinal chemists and discovery scientists to tackle the opportunities we identify in the oncology space. It is our goal to advance safe, effective, and broad-spectrum targeted therapies for cancers that remain inaccessible or become refractory to existing therapy. For more information about our pipeline of innovative drugs, the four technology platforms that fuel our discovery process, partnering, and employment opportunities available with ACB, please visit www.anticancerbio.com. ACB is an equal opportunity employer committed to developing a safe and prosperous work environment.

Founded 2016